Bioptimus

Overview
News
Foundation Models?
Product stageSegments
Minimum Viable Product
?
Fine-tuned language models
?

France-based Bioptimus specializes in drug discovery, utilizing a large-language model (LLM) for the biotechnology sector. Bioptimus aims to adopt AI in understanding and utilizing multi-scale biological data, simplifying complex information to aid in discoveries.

Funding and financials

In February 2024, Bioptimus raised USD 35 million in seed funding led by Sofinnova Partners to integrate AI with biological sciences, aiming for scientific discoveries and personalized medical treatments. Moreover, the company planned to create models that predict and adapt to individual biological scenarios.

HQ location:
14/16 Building Poissonnière Paris FRA
Founded year:
2024
Employees:
1-10
IPO status:
Private
Total funding:
USD 35.0 mn
Last Funding:
USD 35.0 mn (Seed; Feb 2024)
Last valuation:
-
Key competitors
Filter by the segments to which the disruptor belongs
All Segmentsexpand
 
Loading...
Loading...
Loading...
Loading...
Product Overview
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
Product Metrics
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
Company profile
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
Funding data are powered by Crunchbase
arrow
menuarrow
Click here to learn more
Get a demo

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.